PrimeRFP SCOUT · Federal Contract Recompete Brief

80NSSC23CA171E014042 SBIR PHASE III RAPID low-cost — Sachi Bioworks Inc

Sachi Bioworks Inc holds $6.2M across 3 federal awards, concentrated at National Aeronautics and Space Administration (NASA). Competition previously drew 500 offers. Set-aside status: Small business. Recompete timing centers on the Jul 19, 2028 PoP end — agencies typically plan 12–18 months ahead.

Nasa Shared Services Center

Awarding office

Sachi Bioworks Inc

Recipient

Jul 19, 2028

PoP end

$5.4M

Obligated

$9.6M

Potential

541715

NAICS

AJ14

PSC

Small business

Set-aside

500 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Small business

Contract number80NSSC23CA171

AgencyNasa Shared Services Center

Awarding officeNasa Shared Services Center

Awarding agencyNational Aeronautics and Space Administration (NASA)

Funding agencyNational Aeronautics and Space Administration (NASA)

IncumbentSachi Bioworks Inc

CAGE8L8S8

UEINTKPGKZLXPC1

NAICS541715

PSCAJ14

Place of performanceLOUISVILLE CO

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

PoP startJul 10, 2023

PoP end (current)Jul 19, 2028

Obligated$5.4M

Current value$9.6M

Potential value$9.6M

E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE is a federal Small business award for Nasa Shared Services Center held by Sachi Bioworks Inc. Estimated value $9.6M ($5.4M obligated). Current period of performance ends Jul 19, 2028. Last award drew 500 bidders. Place of performance: LOUISVILLE CO.

E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE

Recompete timing

Public

● Expiring in 661 days

Current PoP ends Jul 19, 2028 (661 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jan 19, 2027.

Bonuses end Sept 30

Want the durability read on 80NSSC23CA171? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Sachi Bioworks Inc — $6.2M obligated across 3 awards (firm-wide, all agencies).

Sole agency: National Aeronautics and Space Administration (NASA)

National Aeronautics and Space Administration (NASA)$6.2M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 80NSSC23CA171?

80NSSC23CA171 (E014042 SBIR PHASE III RAPID low-cost) is a Nasa Shared Services Center award with a potential value of $9.6M, currently held by Sachi Bioworks Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 80NSSC23CA171?

Nasa Shared Services Center awarded 80NSSC23CA171 to Sachi Bioworks Inc (potential $9.6M).

Who is the incumbent on 80NSSC23CA171?

Sachi Bioworks Inc is the incumbent with $6.2M across 3 related awards in SCOUT’s public footprint. The current period of performance ends Jul 19, 2028.

When does Sachi Bioworks Inc’s 80NSSC23CA171 come up for recompete?

SCOUT tracks a period-of-performance end of Jul 19, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 80NSSC23CA171? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Aug 20, 2026